Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
The latest trading day saw Bristol Myers Squibb (BMY) settling at $56.29, representing a -0.16% change from its previous close.
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in sales across different uses. Company executives said each treatment type they are studying has multibillion dollar potential, including Alzheimer's disease psychosis, agitation and cognition, along with bipolar disease and autism.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Feedback on schizophrenia treatment has been great, says Bristol Myers Squibb CEO
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment Cobenfy, its oncology business, and more.
Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 10:30 AM ET Company Participants Chris Boerner - Chairman and Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning everybody.
Look Out, Interest Rate Cuts Could Be Over: Buy These High-Yield Passive Income Stars Now
When the Federal Reserve met in December, it threw the stock market and Wall Street a pretty big curveball when it revealed that the dot plot for interest rate cuts for 2025 had been lowered to just two cuts.
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade
Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.
This Unpopular Dividend Stock Is a Buy
Like a champion boxer on the ropes, Bristol-Myers Squibb (BMY -0.58%) finds itself in a challenging position. Specifically, the pharmaceutical giant's shares have declined by a disappointing 11.6% over the prior five years while the benchmark S&P 500 has delivered total returns of 97.5%, including dividends.
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and any dip in the share price can be used as a buying opportunity.
The Magnificent 7 Blue-Chip Dividend Stocks to Buy in 2025 and Hold Forever
Large-capitalization blue-chip dividend stocks are a favorite among investors for a good reason.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
